Label Changes for:

Rebif (Interferon Beta-1a) Injection

April 2013

Changes have been made to the PRECAUTIONS sections of the safety label.

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – April 2013



Pregnancy Category C
  • There are no adequate and well-controlled studies in pregnant women.  Rebif should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus…